MedTrace Logo

Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma

NCT00002681 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2011-06-10

No results posted yet for this study

Summary

RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill leukemia or lymphoma cells. Combining these two therapies may be an effective treatment for leukemia and lymphoma.

PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy plus interleukin-2 in treating patients who have leukemia or lymphoma.

Conditions

Interventions

BIOLOGICAL

aldesleukin

BIOLOGICAL

daclizumab

Sponsors & Collaborators

Principal Investigators

  • Richard P. Junghans, MD, PhD · Beth Israel Deaconess Medical Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-07-31
Primary Completion
2003-09-30
Completion
2003-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002681 on ClinicalTrials.gov